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Abstract
Background: Late-onset sepsis (LOS) in preterm infants is a 
leading cause of mortality and morbidity. Timely recognition 
and initiation of antibiotics are important factors for im-
proved outcomes. Identification of risk factors could allow 
selection of infants at an increased risk for LOS. Objectives: 
The aim was to identify risk factors for LOS. Methods: In this 
multicenter case-control study, preterm infants born at ≤30 
weeks of gestation were included at 9 neonatal intensive 
care units. Detailed demographical and clinical data were 
collected daily up to day 28 postnatally. Clinical and demo-
graphic risk factors were identified using univariate and mul-
tivariate regression analyses in a 1: 1 matched case-control 
cohort. Results: In total, 755 infants were included, including 
194 LOS cases (41 gram-negative cases, 152 gram-positive 
cases, and 1 fungus). In the case-control cohort, every addi-
tional day of parenteral feeding increased the risk for LOS 
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
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(adjusted OR = 1.29; 95% CI 1.07–1.55; p = 0.006), whereas 
antibiotics administration decreased this risk (OR = 0.08; 95% 
CI 0.01–0.88; p = 0.039). These findings could largely be at-
tributed to specific LOS-causative pathogens, since these 
predictive factors could be identified for gram-positive, but 
not for gram-negative, LOS cases. Specifically cephalospo-
rins administration prior to clinical onset was inversely re-
lated to coagulase-negative staphylococcus LOS (CoNS-
LOS) development. Formula feeding was an independent 
risk factor for development of CoNS-LOS (OR = 3.779; 95% CI 
1.257–11.363; p = 0.018). Conclusion: The length of paren-
teral feeding was associated with LOS, whereas breastmilk 
administration was protective against CoNS-LOS. A rapid ad-
vancement of enteral feeding, preferably with breastmilk, 
may proportionally reduce the number of parenteral feed-
ing days and consequently the risk for LOS.
© 2019 The Author(s)
Published by S. Karger AG, Basel
Introduction
Late-onset sepsis (LOS), defined as sepsis onset after 
72 h of life, is a leading cause of mortality in the neonatal 
intensive care unit (NICU) [1]. The incidence rates for 
LOS in preterm infants vary between 20 and 38% in the 
first 120 days of life, and mortality rates range from 13 to 
19% [1–4]. Survivors are at risk for prolonged hospitaliza-
tion, development of necrotizing enterocolitis (NEC), 
bronchopulmonary dysplasia, and neurodevelopmental 
impairment [1, 2, 5]. The diagnosis of LOS in daily clinical 
practice may be challenging, especially in preterm infants, 
as clinical symptoms have limited sensitivity and specific-
ity. The gold standard for diagnosis is confirmation of a 
pathogen in the blood culture, which is limited by subop-
timal sensitivity and delay of a definite diagnosis because 
of the turnaround time to become positive [6]. In addi-
tion, screening of bodily fluids (e.g., blood and urine) may 
also require an invasive procedure, increasing the risk for 
LOS independently [6]. Several studies have identified 
risk factors for LOS, including a lower birth weight, gesta-
tional age (GA), and the presence of central venous cath-
eters [1, 3, 7]. In addition, breastmilk feeding within the 
first month of life has been shown to be protective against 
LOS development [8]. However, most of these studies are 
characterized by a small number of cases, retrospective 
and single-center study designs, and the absence of de-
tailed (daily) clinical data, limiting the possibility of ade-
quate matching with controls and thus the ability to draw 
firm conclusions. Identification of independent risk fac-
tors for LOS in preterm infants may allow selection of in-
fants at an increased risk and the development of novel, 
personalized therapeutic strategies aimed at reducing the 
LOS incidence. Therefore, we aimed to identify indepen-
dent risk factors contributing to the development of LOS 
in preterm born infants in a multicenter case-control 
study with an overview of the clinical characteristics of 
patients with LOS within the first month of life.
Materials and Methods
Patients and Data Collection
This case-control study was conducted between October 2014 
and January 2017 at 2 level II and 7 level III NICU situated in The 
Netherlands and Belgium (online suppl. Table 1; for all online sup-
pl. material, see www.karger.com/doi/10.1159/000497781). None 
of the participating centers administered probiotics routinely. The 
current study was nested in an ongoing study on the identification 
of early diagnostic biomarkers for NEC and LOS [9]. In that study, 
fecal samples and clinical data were collected (if applicable on a 
daily base) from infants born at a GA ≤30 weeks, up to 28 days’ 
postnatal age (Table 1). In order to identify factors associated with 
LOS development the variables were assessed prior to clinical on-
set in the matched case-control cohort. In case of transfer from the 
NICU to a referral hospital or death prior to 28 days’ postnatal age, 
data collection was ceased.
Matching Procedure
From this original cohort, infants diagnosed with LOS were 
strictly matched to 1 healthy control infant based on GA (±3 days), 
birthweight (±10 g), and postnatal age at LOS onset (±0 days). In-
fants who developed LOS as defined below were included as cases, 
and infants who did not develop LOS were included as controls. 
Both cases and controls were excluded in case of early-onset sepsis 
(positive blood cultures < 72 h postnatally) or in case of NEC 
(≥Bell’s stage 2A) or SIP during the follow-up period and an in-
complete or missing medical file.
Definitions
LOS cases were defined as infants with a pathogen isolated 
from the blood culture drawn ≥72 h postnatally and pathogen-
based antibiotic treatment was continued for ≥5 days, according 
to Vermont Oxford criteria [10]. Only the first LOS episode was 
included in the analysis. Isolated pathogens from blood cultures 
were classified into 4 categories: gram-positive bacteria, gram-neg-
ative bacteria, fungi, and coagulase-negative staphylococci (CoNS). 
A CoNS-positive culture was considered a CoNS-LOS when a CRP 
level ≥10 mg/L was measured within 72 h of LOS onset. When ≥2 
pathogens were isolated from the blood culture (one being CoNS), 
the presence of CoNS was considered as contamination. Remain-
ing definitions of collected data are described in Table 1.
Statistical Analysis
Statistical Package for the Social Science (SPSS) version 22.0 
(IBM, Armonk, NY, USA) was used for the statistical analysis. 
First, during the entire inclusion period of 28 days, collected de-
mographic and clinical variables from all infants with LOS were 
compared with non-LOS cases. Potential associations between as-
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sessed variables and the development of LOS were identified via 
univariate logistic regression analysis.
Secondly, in the strictly 1: 1 matched case-control cohort uni-
variate logistic regression analysis was performed on clinical and 
demographical variables in the period preceding the day of LOS 
onset. Subsequently, independent risk factors were identified via 
multivariable regression analysis. This model was constructed us-
ing the backward likelihood ratio method, ultimately including 
statistically significant variables (p value < 0.05). Variables includ-
ed in this model were selected based on their two-tailed p value 
calculated from the univariate regression analyses. Only variables 
with a p value ≤0.30 were included. For every 10 cases one variable 
was included in the multivariable regression analysis. Results were 
considered statistically significant for p values ≤0.05.
Thirdly, potential predictive factors were assessed for the 3 sub-
groups via univariate logistic regression. In addition, independent 
Table 1. Collected variables and definitions
Perinatal variables Postnatal variables
Delivery mode (i.e., vaginal or caesarian section) Gestational age
Single or multiple births Birthweight 
Preterm premature rupture of membranes
(i.e., ≥24 h before delivery)
Apgar score
Meconium-stained amniotic fluid Patent ductus arteriosus
Medication
Antibiotics
1 Total duration of treatment (days)
2 Duration of antibiotic treatment initiated within 24 h postnatally (0, 1–3, or 
>3 days)
3 Antibiotic exposure (yes/no)
Ventilation mode
Diagnosis of necrotizing enterocolitis
Diagnosis of spontaneous intestinal perforation
Diagnosis of sepsis, including the causative pathogen:
1 Gram-positive bacteria (including CoNS)
2 Gram-negative bacteria
3 Fungi
4 CoNS
Number of red blood cell transfusions
Central (umbilical line and/or peripherally inserted central catheter) and 
peripheral venous catheter use:
1 Cumulative number of days a certain line was present
2 Presence of a line within 48 h prior to LOS onset
Parenteral feeding practices (lipids or amino acids)
Enteral feeding practices
1 Breast-fed, defined as the daily average enteral feeding volume consisting of 
>80% breastmilk, including donor milk
2 Formula-fed, defined as the daily average enteral feeding volume consisting of 
>50% formula
3 Combination of breastmilk and formula, that encompasses infants not 
meeting the criteria for (1) and (2)
Time to full enteral feeding, defined as at least 2 consecutive days without 
additional parenteral feeding administration
Radiologic results (i.e., abdominal radiography)
Laboratory results (i.e., C-reactive protein and blood cultures)
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risk factors were identified using multivariable logistic regression 
models. This model was constructed using the forward likelihood 
ratio method, considering the smaller sample size, ultimately in-
cluding statistically significant variables (p value < 0.10). Other sta-
tistical settings remained the same as described for the total 
matched case-control cohort.
All results are displayed as (unadjusted) OR with correspond-
ing 95% CI and p values.
Results
In total, 755 infants were included in the analysis, 
constituting 194 LOS cases (23%). The demographic 
and clinical characteristics of the LOS cases and controls 
in the overall cohort are depicted in online supplemen-
tary Table 2. Further clarification of the LOS incidence, 
the causative pathogen distribution, and the median age 
Table 2. Characteristics of LOS infants and matched controls in the period preceding LOS diagnosis (T0)
LOS 
(n = 194)
Non-LOS 
(n = 194)
Univariate analysis1 p
value
Multivariate
analysis1
p
value
Median gestational age (IQR), weeks+days 27+1 (25+5–28+5) 27+1 (25+5–28+5) 1.000 (0.984–1.017) 0.980
Mean birth weight (±SD), g 965.85±280.21 966.64±273.71 1.000 (0.999–1.001) 0.978
Gender, male, n (%) 106 (54.9) 97 (50.3) 1.206 (0.808–1.799) 0.359
Vaginal delivery, n (%) 89 (46.1) 99 (51.3) 1.078 (0.722–1.609) 0.715
Multiple births, n (%) 74 (38.3) 65 (33.7) 1.208 (0.796–1.833) 0.375
PPROM, n (%) 46 (23.8) 47 (24.4) 0.999 (0.626–1.595) 0.998
Meconium amniotic fluid, n (%) 4 (2.1) 4 (2.1) 1.011 (0.249–4.106) 0.988
Median 1-min Apgar score (IQR) 5 (3–7) 6 (3–7) 0.991 (0.909–1.081) 0.839
Median 5-min Apgar score (IQR) 7 (6–8) 7 (6–8) 0.982 (0.872–1.105) 0.759
PDA, n (%) 76 (39.4) 62 (32.1) 1.430 (0.617–3.315) 0.404
PDA treatment type, n (%)
Ibuprofen 70 (36.3) 59 (30.6) Reference 0.840
Indomethacin 4 (5.4) 2 (3.2) 1.686 (0.298–9.531) 0.555
Surgical 0 1 (1.6) NA 1.000
Central line exposure, n (%) 149 (77.2) 161 (83.4) 0.673 (0.405–1.117) 0.126
Median central line time (IQR), days 8 (6–10) 7 (5–10) 1.028 (0.963–1.097) 0.403
Central line exposure 48 h prior T0, n (%) 111 (57.5) 118 (61.1) 0.860 (0.573–1.292) 0.468
Peripheral line exposure, n (%) 186 (96.4) 187 (96.9) 0.853 (0.281–2.585) 0.778
Median peripheral line time (IQR), days 7 (4–10) 7 (4–9) 1.006 (0.961–1.054) 0.790
Peripheral line exposure 48 h prior T0, n (%) 154 (79.8) 141 (73.1) 1.456 (0.907–2.339) 0.120 1.693 (0.943–3.043) 0.078
Median RBC transfusion time (IQR), days 2 (1–2) 2 (1–2) 1.097 (0.871–1.382) 0.432
Invasive ventilation exposure, n (%) 103 (53.4) 107 (55.4) 0.920 (0.616–1.373) 0.683
Median invasive ventilation time (IQR), days 4 (2–9) 5 (2–9) 1.000 (0.947–1.056) 0.996
Noninvasive ventilation exposure, n (%) 175 (90.7) 166 (86.0) 1.581 (0.840–2.978) 0.156
Median noninvasive ventilation time (IQR), days 7 (4–9) 6 (4–10) 0.996 (0.955–1.040) 0.870
Enteral feeding type, n (%)
Breast milk 80 (41.5) 77 (39.9) Reference 0.716
Formula milk 49 (25.4) 41 (21.2) 1.150 (0.684–1.934) 0.597
Combination 56 (29.0) 59 (30.6) 0.914 (0.565–1.478) 0.713
Achieved full enteral feeding, n (%) 27 (14) 36 (18.7) 0.854 (0.482–1.511) 0.587
Median total of parental feeding time (IQR), days 9 (7–11) 8 (6–10) 1.095 (1.018–1.177) 0.014* 1.125 (1.041–1.216) 0.003*
Total time from birth (days), n (%)
0–5 20 (10.4) 34 (17.6) Reference 0.090
5–10 53 (27.5) 68 (35.2) 1.325 (0.686–2.561) 0.402
>10 55 (28.5) 46 (23.8) 2.033 (1.033–4.000) 0.040*
Medication, n (%)
Inotropes 11 (5.7) 19 (9.8) 0.341 (0.116–1.001) 0.050
Antimycotics 9 (4.7) 11 (5.7) 0.491 (0.158–1.527) 0.219
Postpartum antibiotic administration (days), n (%)
None 27 (14.0) 28 (14.5) Reference 0.872
1–3 111 (57.5) 106 (54.9) 1.086 (0.601–1.963) 0.785
>3 55 (28.5) 59 (30.6) 0.967 (0.508–1.840) 0.918
Antibiotic exposure (yes), n (%) 176 (91.2) 184 (95.3) 0.506 (0.220–1.166) 0.110
Median antibiotic time (IQR), days 4 (3–6) 3 (2–6) 1.027 (0.956–1.103) 0.469
Antibiotic exposure per group, n (%)
Aminoglycoside 150 (77.7) 152 (78.8) 1.177 (0.667–2.076) 0.575
Carbapenem 2 (1.0) 6 (3.1) 0.339 (0.068–1.703) 0.189 0.257 (0.048–1.386) 0.114
Cephalosporin 32 (16.6) 52 (26.9) 0.560 (0.340–0.923) 0.023* 0.562 (0.320–0.987) 0.045*
Glycopeptide
Macrolides
Oxazolidinones
Penicillin (-clavulanic acid)
Quinolones 
Rifampicin 
Trimethoprim-sulfamethoxazole
21 (10.9)
2 (1.0)
0
170 (88.1)
0
0
1 (0.5)
26 (13.5)
4 (2.1)
0
177 (91.7)
0
0
0
0.818 (0.442–1.515)
0.514 (0.093–2.844)
NA
0.960 (0.304–3.036)
NA
NA
NA
0.523
0.446
NA
0.945
NA
NA
NA
Mortality, n (%)
Median age at death (IQR), days
13 (6.7)
17 (10–21)
3 (1.6)
13 (10–13)
4.574 (1.282–16.317)
1.097 (0.869–1.383)
0.019*
0.437
Discharge before 28 days, n (%)
Median age at discharge (IQR), days
50 (25.9)
18 (13–21)
54 (28.0)
18 (12–21)
0.900 (0.574–1.411)
0.996 (0.928–1.068)
0.646
0.905
LOS, late-onset sepsis; NA, not applicable; T0, clinical onset of sepsis; PPROM, preterm premature rupture of membranes; PDA, patent ductus arteriosus; RBC, red blood cells. 1 Values are presented as OR (95% 
CI). * Statistically significant difference.
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of onset are provided in online supplementary Tables 3 
and 4.
Table 2 provides an overview of the demographics and 
characteristics of the LOS cases versus the matched con-
trols (1: 1) irrespectively of the causative pathogen. Dura-
tion of parenteral feeding was identified as an indepen-
dent risk factor for LOS development irrespectively of the 
causative pathogen (OR = 1.125; 95% 1.041–1.216; p = 
0.003). Third-generation cephalosporins administration 
was identified as an independent factor inversely associ-
ated with LOS development (OR = 0.562; 95% CI 0.320–
0.987; p = 0.045). Remaining variables showed no signifi-
cant differences.
Gram-Negative Bacteria
No differences in clinical and demographic character-
istics were found between gram-negative LOS cases and 
controls prior to LOS onset. However, a higher mortality 
rate was observed in LOS cases (unadjusted OR = 11.400; 
95% CI 1.367–95.043; p = 0.025) (Table 3).
Gram-Positive Bacteria
Duration of parenteral feeding (days) was identified as 
an independent risk factor for Gram-positive LOS (OR = 
1.289; 95% CI 1.074–1.547; p = 0.006). Antibiotics expo-
sure prior to clinical onset was inversely related to LOS 
development (OR = 0.078; 95% CI 0.007–0.879; p = 
0.039). Remaining variables showed no significant differ-
ences (Table 4).
Coagulase-Negative Staphylococcus
The total number of days of peripheral line exposure 
(OR = 1.238; 95% CI 1.086–1.411; p = 0.001) and formu-
la feeding (OR = 3.779; 95% CI 1.257–11.363, p = 0.018) 
preceding clinical onset were identified as independent 
risk factors for CoNS-LOS. Administration of third-gen-
eration cephalosporins was found to be an independent 
factor inversely associated with CoNS-LOS (OR = 0.229; 
95% CI 0.086–0.612; p = 0.003). There were no significant 
differences regarding the remaining variables between 
the 2 subgroups (Table 5).
Discussion
This case-control study aimed at identifying demo-
graphic and clinical risk factors associated with the devel-
opment of LOS in preterm infants in a multicenter set-
ting. We demonstrated that every additional day of par-
enteral feeding was associated with an increased risk of 
LOS development. Third-generation cephalosporins ad-
ministration was identified as an independent factor in-
versely associated with the development of CONS-LOS, 
whereas formula feeding was associated with an increased 
risk.
In a previous study, formula-fed infants showed in-
creased odds for CoNS-LOS development compared to 
breast-fed infants [11], and this was confirmed in the cur-
rent study. Breast milk might be protective due to its anti-
infective, microbiome-modulating, and immune-stimu-
latory properties [12]. Several studies have demonstrated 
that infants who receive breastmilk are more likely to 
achieve full enteral feeding at an earlier stage compared 
to formula-fed infants, resulting in earlier cessation of 
parenteral feeding [1, 4, 13]. We demonstrated that expo-
sure to parenteral feeding for more than 10 consecutive 
days was associated with an increased risk of LOS devel-
opment. It could be debated whether clinicians should 
aim to limit the exposure to parenteral feeding to no lon-
ger than 10 days by a more rapid advancement of enteral 
feeding with preferably breastmilk to reduce the risk of 
LOS development. On the contrary, a rapid advancement 
of enteral feeding might increase the risk for NEC devel-
opment. However, studies have shown that rapid ad-
vancement of the enteral feeding volume within the first 
week of life is not significantly associated with NEC in 
preterm and very low birthweight infants [14, 15].
In this study, exposure to antibiotics was associated 
with decreased odds for the development of gram-posi-
tive LOS, irrespectively of the type and duration of anti-
biotics. Cephalosporin exposure was associated with a 
decreased risk for CoNS-LOS, possibly due to the sensi-
tivity of CoNS species to cephalosporins. Therefore, ex-
posure to this agent could reduce the risk of invasion of 
CoNS from either the skin or the gut into the blood-
stream [16, 17]. However, implementation of routine ad-
ministration of cephalosporins in preterm infants re-
mains a topic of debate mainly because of the increased 
risk for colonization with extended-spectrum β-lactamase 
producing bacteria [18]. The observed protective effects 
of early exposure to specific antibiotics against the devel-
opment of LOS indicate that the microbiota may be in-
volved in the pathophysiology of at least a selection of 
LOS cases. The influence of early microbiota coloniza-
tion and alterations in microbiota composition in LOS 
pathophysiology has been considered in several studies 
[19, 20]. This phenomenon might lead to the develop-
ment of strategies aimed at early manipulation of the mi-
crobiota to prevent LOS development, for example by 
administration of probiotics instead of antibiotic pro-
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phylaxis, reducing the risk for colonization with multi-
resistant pathogens [21]. It has been demonstrated that 
probiotic supplementation significantly reduced the risk 
of LOS in preterm infants (n = 9,416) [22]. However, ad-
ditional studies are needed to evaluate the optimal dos-
age, duration, and identification of the best suitable bac-
terial strains for supplementation.
Previous studies have demonstrated an association be-
tween (the duration of) central line exposure and the de-
velopment of LOS in preterm infants [1, 7, 23]. Line ex-
posure significantly increased the risk of gram-positive 
bacteria-related LOS in preterm infants, especially CoNS-
LOS. This increased risk may be caused by contaminated 
intravenous fluids or catheter hubs (intraluminal con-
Table 3. Characteristics of LOS infants caused by gram-negative bacteria and matched controls in the period preceding LOS diagnosis 
(T0)
Characteristic LOS (n = 39) Non LOS (n = 39) Univariate analysis1 p value
Median gestational age (IQR), weeks+days 26+2 (25+2–28+1) 6+2 (25+2-28+1) 1.000 (0.964–1.038) 0.992
Median birth weight (IQR), g 930.0 (740.0–1170.0) 865 (760.0–1135.0) 1.000 (0.998–1.001) 0.985
Male gender, n (%) 19 (48.7) 22 (56.4) 0.734 (0.301–1.790) 0.497
Vaginal delivery, n (%) 24 (61.5) 25 (64.1) 1.116 (0.445–2.797) 0.815
Multiple births, n (%) 13 (33.3) 16 (41.0) 0.719 (0.286–1.807) 0.483
PPROM, n (%) 7 (17.9) 11 (28.2) 0.557 (0.190–1.631) 0.286
Meconium amniotic fluid, n (%) 1 (2.6) 1 (2.6) 1.000 (0.060–16.594) 1.000
Median 1-min Apgar score (IQR) 5 (3–6) 6 (4–7) 0.885 (0.721–1.086) 0.242
Median 5-min Apgar score (IQR) 7 (6–8) 7 (6–8) 0.901 (0.668–1.217) 0.497
PDA, n (%) 18 (46.2) 14 (35.9) 0.643 (0.053–7.832) 0.729
PDA treatment type, n (%)
Ibuprofen
Indomethacin
Surgical
15 (38.5)
0
2 (5.1)
13 (33.3)
0
1 (2.6)
NA
NA
NA
NA
NA
NA
Central line exposure, n (%)
Median central line time (IQR), days
Central line exposure 48h prior T0, n (%)
36 (92.3)
8 (5–12)
27 (69.2)
34 (87.2)
8 (5–11)
23 (59.0)
1.765 (0.391–7.958)
1.006 (0.899–1.125)
1.565 (0.616–3.977)
0.460
0.923
0.346
Peripheral line exposure, n (%)
Median peripheral line time (IQR), days
Peripheral line exposure 48h prior T0, n (%)
36 (92.3)
8 (5–10)
32 (82.1)
38 (97.4)
8 (4–10)
31 (79.5)
0.316 (0.031–3.177)
1.029 (0.923–1.148)
1.180 (0.382–3.646)
0.328
0.607
0.774
Median RBC transfusions (IQR), n 2 (1–2) 2 (1–3) 1.094 (0.728–1.646) 0.665
Invasive ventilation exposure, n (%)
Median invasive ventilation time (IQR), days
23 (59.0)
6 (2–12)
19 (48.7)
11 (5–13)
1.513 (0.618–3.704)
0.925 (0.815–1.050)
0.364
0.228
Noninvasive ventilation exposure, n (%)
Median noninvasive ventilation time (IQR), days
34 (87.2)
8 (5–10)
31 (79.5)
8 (5–11)
1.755 (0.519–5.937)
0.962 (0.867–1.068)
0.366
0.471
Enteral feeding type, n (%)
Breast milk
Formula milk
Combination
Achieved full enteral feeding, n (%)
20 (51.3)
3 (7.7)
12 (30.8)
5 (12.8)
22 (56.4)
8 (20.5)
7 (17.9)
8 (21.1)
Reference
0.413 (0.096–1.774)
1.886 (0.620–5.731)
0.595 (0.166–2.218)
0.179
0.234
0.263
0.595
Median total parental feeding time (IQR), days
Total time from birth (days), n (%)
0–5
5–10
>10
9 (7–13)
6 (15.4)
13 (33.3)
12 (30.8)
9 (7–11)
4 (10.3)
17 (43.6)
10 (25.6)
1.079 (0.940–1.240)
Reference
0.510 (0.119–2.188)
0.800 (0.175–3.651)
0.280
0.575
0.365
0.773
Medication, n (%)
Inotropes
Antimycotics
5 (12.8)
1 (2.6)
3 (7.7)
3 (7.7)
1.000 (0.132–7.570)
0.167 (0.012–2.368)
1.000
0.186
Postpartum antibiotic administration time (days), 
n (%)
None
1–3
>3
4 (10.3)
26 (66.7)
9 (23.1)
2 (5.1)
23 (59.0)
14 (35.9)
Reference
0.565 (0.095–3.378)
0.321 (0.048–2.133)
0.388
0.532
0.240
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tamination) or by skin-colonizing organisms invading 
the bloodstream via the catheter track (extraluminal con-
tamination) [24]. We observed that every additional day 
that a peripheral line was present the risk of CoNS-LOS 
increased, while central line exposure (presence/absence 
and duration) was not an independent risk factor for 
CoNS-LOS. The apparent discrepancy in the study results 
might be explained by differences in study design. The 
majority of preterm infants have either a central or a pe-
ripheral line during the first month of life, and a younger 
GA is associated with an increased risk for LOS [1, 7]. In 
the current study we matched study participants on GA 
to prevent bias by this age-related catheter exposure. A 
positive association between the dwell time of peripheral 
catheters and central venous lines and LOS development 
has been described in several studies, although the results 
are contradictory [23, 25, 26]. We found no association 
between the dwell time of both central and peripheral 
catheters and LOS. We hypothesized that an increased 
risk of LOS development is not merely influenced by the 
dwell time of either central or peripheral lines but pre-
dominantly by frequent replacement of central and/or 
peripheral catheters. This may increase the risk of inser-
tion of potential causative pathogens by contaminated 
catheter hubs or by creation of new entrance sites [25, 26]. 
However, this variable was not taken into account in the 
present study.
This study has several strengths; detailed data collec-
tion in a multicenter design allowed for a strictly matched 
case-control comparison and the relatively large sample 
size allowed to determination of predictive factors per 
subgroup of causative pathogens. This study has also sev-
eral limitations that need to be addressed. First, data col-
lection was limited to the first 28 days postnatally, which 
might have resulted in a lower LOS incidence and mor-
tality rate. Hypothetically, limiting data collection until a 
postnatal age of 28 days might also result in allocation of 
infants into the control group while they might have de-
veloped sepsis after the defined follow-up period, there-
fore possibly resulting in an underestimation of the po-
tential risk factors. Secondly, this study contained limit-
ed obstetric data. This could hypothetically have 
influenced the outcome, since maternal factors may also 
include risk factors for LOS as they have been described 
to influence the neonatal immune system. Thirdly, cen-
ter-specific effects could not be excluded from the analy-
ses due to variating LOS incidences, limiting center-
based matching. However, this could allow for identifica-
tion of factors leading to an increased risk for LOS 
development as a result of local protocols used. Lastly, 
prolonged parenteral nutrition could also be seen as an 
early sign of LOS, particularly in less-fulminant CoNS-
LOS, rather than a preonset risk factor. However, the rel-
atively large number of LOS cases allowed us to focus on 
Characteristic LOS (n = 39) Non LOS (n = 39) Univariate analysis1 p value
Antibiotic exposure (yes), n (%)
Median antibiotics time (IQR), days
Antibiotic exposure per group, n (%)
Aminoglycosides
Carbapenems
Cephalosporins
Glycopeptides
Macrolides
Oxazolidinones
Penicillins (-clavulanic acid)
Quinolones
Rifampicin
Trimethoprim-sulfamethoxazole
36 (92.3)
3 (3–8)
31 (79.5)
1 (2.6)
9 (23.1) 
3 (7.7)
0
0
36 (92.3)
0
0
1 (2.6)
39 (100)
3 (3–8)
30 (76.9)
3 (7.7)
13 (33.3)
6 (15.4)
4 (10.3)
0
37 (94.9)
0
0
0
NA
1.025 (0.887–1.184)
1.447 (0.413–5.063)
0.324 (0.032–3.268)
0.615 (0.224–1.693)
0.470 (0.108–2.043)
NA
NA
NA
NA
NA
NA
0.999
0.740
0.563
0.339
0.347
0.314
NA
NA
1.000
NA
NA
NA
Mortality, n (%)
Median age at death (IQR), days
9 (23.1)
17 (12–19)
1 (2.6)
10 (NA)
11.400 (1.367–95.043)
NA
0.025*
0.998
Discharge before 28 days, n (%)
Median age at discharge (IQR), days
13 (33.3)
18 (15–21)
8 (20.5)
15 (10–21)
1.937 (0.696–5.391)
1.093 (0.878–1.362)
0.205
0.425
LOS, late-onset sepsis; NA, not applicable; T0, clinical onset of sepsis; PPROM, preterm premature rupture of membranes; PDA, 
patent ductus arteriosus; RBC, red blood cells. 1 Values are presented as OR (95% CI). * Statistically significant difference.
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risk factors per pathogen. So, this possible limitation may 
only account for CoNS-LOS cases. In the case of other 
pathogens, the course of sepsis is considered to be more 
fulminant.
In conclusion, since in the current study parenteral 
feeding was strongly associated with LOS development, it 
could be hypothesized that reduction of the number of 
parenteral feeding days might reduce the risk of LOS, 
which may be achieved by advancement of enteral feed-
ing, preferably with breastmilk. Protective effects of early 
exposure to specific antibiotics underline the increasing 
notion that a disturbed microbial colonization may be in-
volved in the pathophysiology of at least a selection of 
LOS cases.
Table 4. Characteristics of LOS infants caused by gram-positive bacteria and matched controls in the period preceding LOS diagnosis 
(T0)
LOS (n = 152) Non-LOS (n = 152) Univariate analysis1 p
value
Multivariate
analysis1
p
value
Median gestational age (IQR), weeks+days 27+4 (25+6–28+5) 27+4 (25+6–28+5) 1.000 (0.981–1.020) 0.981
Mean birth weight (±SD), g 965.8 (274.7) 968.0 (273.3) 1.000 (0.999–1.001) 0.944
Male gender, n (%) 85 (55.9) 74 (48.7) 1.337 (0.852–2.100) 0.207
Vaginal delivery, n (%) 64 (42.1) 84 (55.3) 1.075 (0.682–1.695) 0.755
Multiple births, n (%) 60 (39.5) 48 (31.5) 1.413 (0.881–2.265) 0.151
PPROM, n (%) 39 (25.7) 35 (23.0) 1.197 (0.707–2.026) 0.503
Meconium amniotic fluid, n (%) 3 (2.0) 2 (1.3) 1.521 (0.250–9.242) 0.649
Median 1-min Apgar score (IQR) 6 (3–7) 5 (3–7) 1.011 (0.917–1.114) 0.827
Median 5-min Apgar score (IQR) 7 (6–9) 7 (7–8) 0.991 (0.870–1.129) 0.890
PDA, n (%) 66 (43.4) 59 (38.8) 1.206 (0.740–1.966) 0.453
PDA treatment type, n (%)
Ibuprofen
Indomethacin
Surgical
54 (35.5)
0
2 (1.3)
45 (29.6)
1 (0.7)
1 (0.7)
Reference
NA
1.667 (0.146–18.985)
0.919
1.000
0.681
Central line exposure, n (%)
Median central line time (IQR), days
Central line exposure 48h prior T0, n (%)
111 (73)
8 (6–9)
83 (54.6)
125 (82.2)
7 (5–10)
94 (61.8)
0.585 (0.338–1.012)
1.034 (0.953–1.121)
0.742 (0.470–1.172)
0.055
0.420
0.201
Peripheral line exposure, n (%)
Median peripheral line time (IQR), days
Peripheral line exposure 48 h prior T0, n (%)
148 (97.4)
7 (4–10)
120 (78.9)
147 (96.7)
7 (4–9)
108 (71.1)
1.259 (0.331–4.780)
1.006 (0.955–1.060)
1.528 (0.904–2.581)
0.736
0.812
0.113
Median RBC transfusions (IQR), n 2 (1–2) 2 (1–2) 1.091 (0.823–1.444) 0.545
Invasive ventilation exposure, n (%)
Median invasive ventilation time (IQR), days
26 (17.1)
4 (2–9)
38 (25.0)
5 (2–9)
2.098 (0.974–4.519)
1.011 (0.949–1.076)
0.058
0.740
Noninvasive ventilation exposure, n (%)
Median noninvasive ventilation time (IQR), days
139 (91.4)
6 (4–9)
133 (87.5)
6 (4–9)
1.527 (0.726–3.216)
1.003 (0.956–1.052)
0.265
0.912
Enteral feeding type, n (%)
Breast milk
Formula milk
Combination
Achieved full enteral feeding, n (%)
58 (38.2)
46 (30.3)
44 (28.9)
22 (14.4)
55 (36.2)
32 (21.1)
52 (34.2)
28 (18.2)
Reference
1.363 (0.761–2.441)
0.802 (0.465–1.384)
0.938 (0.495–1.780)
0.227
0.297
0.429
0.846
Median total parental feeding time (IQR), days 9 (7–11) 8 (5–10) 1.102 (1.010–1.202) 0.029* 1.289 (1.074–1.547) 0.006*
Total time from birth (days), n (%)
0–5
5–10
>10
14 (9.2)
55 (36.2)
26 (17.1)
30 (19.7)
65 (42.8)
20 (13.2)
Reference
1.813 (0.875–3.759)
2.786 (1.177–6.593)
0.066
0.110
0.020*
Medication, n (%)
Inotropes
Antimycotics
6 (3.9)
8 (5.3)
16 (10.5) 0.188 (0.048–0.728)
0.791 (0.211–2.972)
0.016*
0.729
Postpartum antibiotics administration (days), n (%)
None
1–3
>3
22 (14.5)
84 (55.3)
46 (30.3)
26 (17.1)
81 (53.3)
45 (29.6)
Reference
1.226 (0.643–2.335)
1.208 (0.599–2.435)
0.820
0.536
0.597
Antibiotic exposure (yes), n (%)
Median antibiotics time (IQR), days
Antibiotic exposure per group, n (%)
Aminoglycosides
Carbapenems
Cephalosporins
Glycopeptides
Macrolides
Oxazolidinones
Penicillins (-clavulanic acid)
Quinolones 
Rifampicin 
Trimethoprim-sulfamethoxazole
138 (90.8)
4 (3–6)
117 (77.0)
1 (0.7)
23 (15.1)
18 (11.8)
2 (1.3)
0
132 (86.8)
0
0
0
143 (94.1)
3 (2–6)
121 (79.6)
3 (2.0)
38 (25.0)
19 (12.5)
0
0
138 (90.8)
0
0
0
0.620 (0.260–1.480)
1.032 (0.950–1.121)
1.059 (0.556–2.016)
0.343 (0.035–3.338)
0.558 (0.312–0.998)
0.987 (0.494–1.971)
NA
NA
0.957 (0.301–3.040)
NA
NA
NA
0.282
0.462
0.861
0.357
0.049*
0.970
NA
NA
0.940
NA
NA
NA
0.078 (0.007–0.879) 0.039*
Mortality, n (%)
Median age at death (IQR), days
4 (2.6)
16 (6–25)
2 (1.3)
15 (NA)
2.027 (0.366–11.235)
1.018 (0.811–1.278)
0.419
0.878
Discharge before 28 days, n (%)
Median age at discharge (IQR), days
55 (36.2)
18 (13–22)
50 (32.9)
19 (12–22)
1.157 (0.721–1.857)
0.985 (0.913–1.062)
0.547
0.693
LOS, late-onset sepsis; NA, not applicable; T0, clinical onset of sepsis; PPROM, preterm premature rupture of membranes; PDA, patent ductus arteriosus; RBC, red blood cells. 1 Values are presented as OR (95% 
CI). * Statistically significant difference. 
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Table 5. Characteristics of infants with LOS caused by CoNS bacteria and matched controls in the period preceding LOS diagnosis (T0)
LOS 
(n = 111)
Non-LOS
(n = 111)
Univariate analysis1 p value Multivariate analysis1 p value
Median gestational age (IQR), weeks+days 27+4 (25+6–28+6) 27+4 (25+6–28+6) 1.000 (0.979–1.022) 0.991
Median birth weight (IQR), g 930 (725–1,180) 900 (750–1,190) 1.000 (0.999–1.001) 0.940
Male gender, n (%) 61 (55) 54 (48.6) 1.288 (0.760–2.183) 0.347
Vaginal delivery, n (%) 46 (41.1) 50 (45.0) 1.105 (0.648–1.885) 0.715
Multiple births, n (%) 42 (37.8) 31 (27.9) 1.571 (0.893–2.763) 0.117
PPROM, n (%) 32 (28.8) 27 (24.3) 1.312 (0.720–2.390) 0.375
Meconium-stained amniotic fluid, n (%) 2 (1.8) 1 (0.9) 2.020 (0.180–22.622) 0.569
Median 1-min Apgar score (IQR) 5 (3–7) 5 (3–7) 1.018 (0.906–1.143) 0.767
Median 5-min Apgar score (IQR) 7 (6–8) 7 (6–8) 0.986 (0.850–1.143) 0.850
PDA, n (%)
PDA treatment type, n (%)
Ibuprofen
Indomethacin
Surgical
39 (35.1)
36 (32.4)
0
2 (1.8)
31 (27.9)
30 (27.0)
1 (0.9)
0
1.677 (0.627–4.490)
Reference
NA
NA
0.303
1.000
1.000
0.999
Central line exposure, n (%)
Median central line time (IQR), days
Central line exposure 48h prior T0, n (%)
77 (69.4)
7 (6–9)
62 (55.9)
94 (84.7)
7 (5–9)
78 (70.3)
0.410 (0.213–0.789)
1.050 (0.937–1.176)
0.535 (0.308–0.931)
0.008*
0.403
0.027*
Peripheral line exposure, n (%)
Median peripheral line time (IQR), days
Peripheral line exposure 48 h prior T0, n (%)
107 (96.4)
6 (4–9)
89 (80.2)
107 (96.4)
6 (4–8)
77 (69.4)
1.000 (0.244–4.102)
1.060 (0.981–1.146)
1.786 (0.964–3.311)
1.000
0.142
0.065
1.238 (1.086–1.411) 0.001*
Median RBC transfusions (IQR), n 2 (1–3) 1 (1–2) 1.217 (0.836–1.770) 0.305
Invasive ventilation exposure, n (%)
Median invasive ventilation time (IQR), days
54 (48.6)
4 (3–8)
64 (57.7)
5 (2–9)
0.696 (0.410–1.181)
1.012 (0.918–1.117)
0.179
0.804
Noninvasive ventilation exposure, n (%)
Median noninvasive ventilation time (IQR), days
103 (92.8)
6 (4–9)
96 (86.5)
6 (4–8)
2.012 (0.816–4.958)
0.996 (0.928–1.070)
0.129
0.922
Enteral feeding type, n (%)
Breast milk
Formula milk
Combination
Achievement of full enteral feeding
35 (31.5)
38 (34.2)
37 (33.3)
22 (14.4)
37 (33.3)
23 (20.7)
41 (36.9)
28 (18.2)
Reference
1.747 (0.873–3.496)
0.954 (0.502–1.811)
0.938 (0.495–1.780)
0.171
0.115
0.954
0.846
Reference
3.779 (1.257–11.363)
0.782 (0.328–1.865)
0.019*
0.018*
0.580
Median total parental feeding time (IQR), days
Total time from birth (days), n (%)
0–5
5–10
>10
8 (7–10)
8 (7.2)
34 (30.6)
18 (16.2)
8 (5–9)
23 (20.7)
44 (39.6)
18 (16.2)
1.075 (0.967–1.193)
Reference
2.222 (0.885–5.578)
2.875 (1.020–8.104)
0.180
0.122
0.089
0.046*
Medication, n (%)
Inotropes
Antimycotics 
2 (1.8)
3 (2.7)
11 (9.9)
5 (4.5)
0.104 (0.015–0.726)
0.382 (0.069–2.125)
0.022*
0.272
Postpartum antibiotics administration (days), n (%)
None
1–3
>3
14 (12.6)
66 (59.5)
31 (27.9)
18 (16.2)
60 (54.1)
33 (29.7)
Reference
1.414 (0.648–3.088)
1.208 (0.515–2.865)
0.656
0.384
0.665
Antibiotic exposure (yes), n (%)
Median antibiotics time (IQR), days
Antibiotic exposure per group, n (%)
Aminoglycosides 
Carbapenems
Cephalosporins 
Glycopeptides 
Macrolides 
Oxazolidinones 
Penicillins (-clavulanic acid)
Quinolones 
Rifampicin 
Trimethoprim- sulfamethoxazole
104 (93.7)
4 (3–6)
92 (82.9)
0
13 (11.7)
9 (8.1)
1 (0.9)
0
100 (90.1)
0
0
0
107 (93.7)
3 (2–6)
89 (80.2)
3 (2.7)
27 (24.3)
15 (13.5)
0
0
100 (90.1)
0
0
0
1.000 (0.339–2.952)
1.043 (0.932–1.167)
1.504 (0.661–3.418)
NA
0.417 (0.202–0.864)
0.574 (0.239–1.379)
NA
NA
1.667 (0.388–7.162)
NA
NA
NA
1.000
0.460
0.330
NA
0.019*
0.215
NA
NA
0.492
NA
NA
NA
0.229 (0.086–0.612) 0.003*
Mortality, n (%)
Median age at death (IQR), days
1 (0.9)
5 
2 (1.8)
15
0.495 (0.044–5.544)
NA
0.569
NA
Discharge before 28 days, n (%)
Median age at discharge (IQR), days
41 (36.9)
18 (13–21)
40 (36.0)
19 (12–22)
1.040 (0.602–1.796)
0.989 (0.909–1.077)
0.889
0.807
LOS, late-onset sepsis; NA, not applicable; T0, clinical onset of sepsis; PPROM, preterm premature rupture of membranes; PDA, patent ductus arteriosus; RBC, red blood cells. 1 Values are presented as OR (95% 
CI). * Statistically significant difference.
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